U.S. Healthcare Spending to Surpass $6 Trillion in 2026, with GLP-1 Drugs as a Key Driver
Miles Bennett
CMS projects US healthcare spending will break $6 trillion in 2026, with prescription-drug costs rising 8.2% — faster than every other category. The surge in GLP-1 obesity drugs is reshaping the spending structure, and both taxpayers and patients will feel it directly.
Why are prescription drugs outpacing every other healthcare category?
US prescription-drug spending is projected to exceed $560 billion in 2026, up 8.2% year-on-year — faster than hospital care, outpatient services, or any other major segment.
This means → drug prices alone don't explain the jump. The number of people taking these drugs is expanding — more Americans are filling prescriptions they never would have before.
CMS deputy director John Poisal was explicit: "A large part of this is from GLP-1s."
How many Americans are actually using GLP-1 drugs?
A 2025 KFF poll found nearly one in five US adults has taken a GLP-1 drug at some point.
About one in four of those users paid out of pocket. Out-of-pocket prescription spending is expected to rise 5% in 2025, partly because consumers are covering weight-loss drugs themselves.
In plain terms = GLP-1s are no longer a niche prescription — they are approaching a mass-market product, yet many users are paying the full tab.
Where is the government's money going — and why is Medicare under sudden pressure?
Medicare spending is projected to hit $1.3 trillion in 2026, up 9.2%, driven by baby boomers accelerating into the program.
In April, the Trump administration dropped the plan to have insurers cover GLP-1 drugs for seniors and shifted the cost to Medicare — funded by taxpayers — through the end of next year.
This means → the GLP-1 bill is moving from individuals and insurers onto the public balance sheet, amplifying Medicare's spending pressure.
How will shifting policy reshape coverage?
Last November, Eli Lilly and Novo Nordisk each struck deals with the Trump administration: lower prices in exchange for tariff exemptions and broader Medicare access.
The "One Big Beautiful Bill," signed in July 2025, adds work requirements to Medicaid eligibility for some adults — a move expected to shrink Medicaid enrollment.
This reflects two forces pulling in opposite directions: GLP-1 coverage is expanding while Medicaid is tightening — the net effect on total spending depends on which force moves faster.
How long can GLP-1 growth last?
CMS projects the GLP-1 market's growth momentum will start to slow around 2030.
Whether that slowdown arrives on schedule hinges on two variables: the progress of drug-price negotiations and the final shape of coverage policy.
In plain terms = 2030 is an aspiration, not a certainty — if coverage keeps expanding and prices don't come down, the inflection point could slip further out.
Content is for reference only, not financial advice.